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Abstract Assessing pain intensity in (preverbal) children is
more difficult than in adults. Tools to measure pain are
being used as primary endpoints [e.g., pain intensity, time
to first (rescue) analgesia, total analgesic consumption,
adverse effects, and long-term effects] in studies on the
effects of analgesic drugs. Here, we review current and
promising new endpoints used in pediatric pain assessment
studies.
Keywords Pain.Assessment.Pharmacokinetics.
Pharmacodynamics.Long-term outcome
Introduction
Neurobiology of pediatric pain: essentials for drugs-related
studies
The neonatal stage of life is characterized by a high
sensitivity to pain and a great vulnerability to neuronal cell
death [1]. Anecdotal reports have shown prolonged
allodynia and hyperalgesia after pain and tissue damage
within the first weeks of life that extend beyond the period
associated with tissue healing [2–7]. For example, 4- to 6-
month-old term infants who had undergone circumcision
responded more intensely to immunization than did their
uncircumcised peers [5]. In another study, however, in
comparison to age-matched controls, children who had
undergone major surgery in combination with preemptive
analgesia within the first months of life did not show
different behavioral pain responses and saliva cortisol
concentrations at 14 and 45 months of age when exposed
to vaccinations [8]. Thus, the question is, therefore, whether
the preemptive administration of analgesics indeed prevents
possible long-term consequences of neonatal pain. Animal
experiments have provided a number of clues. In a rodent
model, neonatal nerve ligation led to long-term hyper-
algesia that was not attenuated when local anesthetics were
administered [9]. Also in the rat, neonatal exposure to
carrageen or Complete Freud adjuvant (CFA) led to either
hyposensitivity or no alterations; however, when the adult
animals were re-exposed to inflammatory pain, there was a
hypersensitivity reaction [10–14]. In contrast, formalin
injections or laparotomy in newborn rats were found to
lead to thermal hyposensitivity at an adult age [13–15],
which was attenuated by morphine administration [15].
Tissue damage and neonatal pain disturb the normal
development of the nociceptive neural circuits, as expressed
by structural and functional neuroanatomical changes at
both the peripheral [9, 16, 17] and spinal cord level [11,
18]. Moreover, changes in spinal gene expression involved
in the transmission of nociception have been documented
[13]. These animal experiments may provide an explanation
for the long-term effects found in human children.
In summary, at present, we do not know whether
adequate analgesia prevents the development of long-term
alterations in pain sensitivity and if such alterations do
occur, whether they will be restricted to the dermatome of
tissue injury (spinal changes) or be generalized all over the
body (supraspinal changes) [4].
Exposing neonates to pain or tissue damage is develop-
mentally inappropriate, and analgesics may not prevent
them from developing subsequent pain hypersensitivity.
The next logical question is whether this pain hypersensi-
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DOI 10.1007/s00228-010-0947-6tivity will still exist 15 years after tissue injury or whether it
has recovered or reverted to hyposensitivity. The few
studies on this aspect of pain management provide no or
little information on the total analgesic dosages during
hospital stay [19, 20]. It would seem, therefore, that more
randomized controlled trials (RCTs) on analgesics are
needed in children as well as follow-up studies in these
same patients through childhood and adolescence in order
to gain insight into the long-term effects of neonatal pain
and neonatal analgesia.
Endpoints in clinical trials
A clinical trial endpoint is a measure that allows
researchers to decide whether the null hypothesis of a
clinical trial should be accepted or rejected [21]. Possible
endpoints in pediatric analgesic trials are: pain intensity,
time to first (rescue) analgesia, total analgesic consump-
tion, adverse effects, and long-term effects [22, 23]. RCTs
may have more than one endpoint, in which case it is
customary to differentiate between primary and secondary
outcomes.
Assessing pain intensity in (preverbal) children is more
difficult than in adults. Adults’ self report of pain is
generally accepted as the gold standard [International
Association for the Study of Pain (IASP)] of pain
assessment. However, the discussion merely limits itself
to the question of which of the available self report scales is
most appropriate in a given situation. Pain intensity in
young children can be assessed with validated observational
pain assessment instruments or multidimensional pain
assessment instruments that include both behavioral and
physiological parameters. Self report is feasible from the age
of 4–5 years. Because observational pain instruments
provide subjective outcomes, it is crucial that observers are
well trained and that interrater reliability has been tested and
proven to be good. Establishing cutoff points that differen-
tiate between different levels of pain intensity is an important
requirement because rescue medication is given when scores
exceed specific values.
An important reference article is the one from the
Pediatric Initiative on Methods, Measurement, and Pain
Assessment in Clinical Trials (Ped-IMMPACT), in which
core domains and measures for clinical pain trials have
been defined [22].
The type of outcome measure also depends on the type
of pain under study. Physiological parameters, for
example, are more promising for acute painful proce-
dures, such as heel lances or venipunctures, than for
chronic pain. The different types of endpoints will be
presented with a focus on postoperative pain in the
following section.
Behavioral assessments
The IASP emphasizes that the inability to communicate
verbally does not negate the possibility that an individual is
experiencing pain and is in need of appropriate pain-relieving
treatment [24]. Based on this standpoint, behavioral-based
pain observation instruments have been developed. The
Children's Hospital Eastern Ontario Pain Scale (CHEOPS)
[22, 25] and the Faces, Legs, Arms, Cry and Consolability
(FLACC) pain scale [26, 27] have been validated for
assessing postoperative pain in 1- to 7-year-old children. To
this end, the COMFORT-behavior scale has been validated
in 0- to 3-year-old children in the intensive care setting [28].
These scales have several items in common, namely, facial
expression, crying, and body movements.
Children with severe intellectual disabilities may show
idiosyncratic behavior when they are in pain. Thus, the
application of pain scales developed for children without
intellectual disabilities to those children with such disabil-
ities has been advised against [29, 30]. At least four
validated postoperative pain instruments for children with
intellectual disabilities have been developed. One of these
is the revised FLACC, which allows for individualized
behavior added to each of the five items of the scale. This
pain scale has been validated for postoperative pain [31]
and proved to have a high degree of clinical utility [32].
The second scale is the Paediatric Pain Profile (PPP), a 20-
item scale that has been validated for postoperative pain
[33, 34]. The PPP consists of three sets of recordings: two
retrospective parent ratings of the child’s behavior—i.e.,
when the child was at his or her best and during painful
episodes, respectively—and a prospective rating by the
nurse, for example, postoperatively. Although it may take
more time to complete the PPP than the FLACC, use of the
PPP may be well worthwhile for research purposes. The
third scale is the non-communicating children’s pain checklist
(NCCPC) [35] of which the postoperative version (NCCPC-
PV) [36] includes 27 items and requires a 10-min observa-
tion. A fourth scale is the Checklist Pain Behaviour (CPB),
which has been validated for postoperative pain and been
reduced without any loss of information to a ten-item version
[37, 38]. In addition, a recent study has described the use of
an individualized Numeric Rating Scale based solely on the
child’s individual pain indicators as described by the parents
and caregivers [39].The psychometric properties of this scale
are promising; nevertheless, the essential involvement of the
parents may be a drawback, especially when the scale is to
be used for research purposes [40].
Self report
An example of a self-report tool for 2- to 3-year-old
toddlers is the Poker Chip Tool [41], while the Faces Pain
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children aged over 4 years [42, 43]. The Numeric Rating
Scale pain (NRS-11) [44] and Visual Analogue Scale pain
(VAS) [45] should preferably not be used in children less
than 8 years old because both require a certain cognitive
level of development to translate pain intensity into
numbers or distances on a 10-cm ruler. The Poker Chip
Tool, Faces Pain Scale-revised, and VAS have also been
recommended as valid self-report tools by the Pediatric
Initiative on Methods, Measurements and Pain Assessment
in Clinical Trials (PedIMMPACT) and in two reviews [22,
43, 46].
Physiological parameters
As behavior-based assessment instruments remain subjective,
researchers continue to search for neurobiological-based and
more ‘objective’ parameters of pain intensity [47]. Several
instruments indeed go some way to meeting this aim of
increased objectivity by including physiological items as
well, such as the PIPP and the COMFORT scale [48, 49].
However, heart rate and blood pressure have proven to be
insufficiently sensitive for postoperative pain assessment,
probably because treatment, blood loss, fever, and other
clinical conditions will influence these parameters [50, 51].
New methods, such as near-infrared spectroscopy (NIRS)
and skin conductance, may help to objectify pain or stress in
nonverbal humans. NIRS measures regional changes in the
concentration of oxygenated and deoxygenated hemoglobin.
This technique is based on the assumption that increased
tissueoxygenationrepresentsagreaterregionalcerebralblood
flow. This, in turn, is associated with higher neuronal activity,
as seen in noxious events (encoded by the frequency of firing
and number of activated neurons) [52]. The use of NIRS in
pediatrics has been limited to the assessment of acute pain in
neonates [53–55]. In one study, researchers compared NIRS
measurements with facial expression during 33 heel lance
procedures in 12 stable newborns and found that brain
activity in most of the newborns was related to facial
expression. However, some newborns did not show a change
in facial expression even though NIRS readings revealed
increased cortical activity during the procedure [54].
The measurement of stress by skin conductance is based
on neurophysiological arousal, with increased activity in
the sympathetic nervous system leading to sweating in the
palms of the hand and the foot soles. As such, the level of
increase may serve as a surrogate measure of stress and not
of pain per se [56].
Biomarkers
Hormonal stress markers, such as salivary cortisol and (nor)
epinephrine, may have additional value in the context of
analgesia trials [57]. Nevertheless, because stress and pain
are correlated but difficult to distinguish, these hormone
levels should not be considered as primary endpoints of
pain studies. Age-dependent differences in hormonal
levels as well as age-dependent differences in circadian
rhythm are important confounders. This is especially true
in postoperative patients in whom the extent and duration
of the so-called hormonal stress response are highly
determined by age [57]. However, salivary cortisol could
be a substitute marker for pain or stress in severely
cognitively impaired children. Remarkably, RCTs in this
vulnerable patient group have not yet been performed
despite the fact that co-medication, such as anticonvul-
sants, could influence opioid use during surgery, as
reported in a single study from 1990, which has to date
never been replicated [58].
Brain activity-related parameters
Experimental approaches involving the use of functional
magnetic resonance imaging (fMRI) and positron emission
tomography (PET) scans have been tested in the research
setting only [59, 60]. PET scans performed solely for
pediatric research reasons may, however, meet with ethical
and practical obstacles as they involve the administration of
radioactively labeled drugs. As a noninvasive procedure,
fMRI is more promising for the (semi)clinical evaluation of
children and can be combined with quantitative sensory
testing [61]. Neurophysiological measurements, such as the
electroencephalogram (EEG) and somatosensory response,
have so far not identified a specific pain signal that could be
useful in daily clinical practice. There is direct EEG
evidence of specific noxious-evoked neural activity in the
infant brain [62]. Somato-sensory responses have been
demonstrated in young infants, but these cannot yet serve as
endpoints; we first need to establish normal values of
voltage, frequency, and duration.
Time to first (rescue) analgesia and analgesic consumption
As many postoperative patients will receive preemptive
analgesic drugs, time to first rescue analgesia may serve as a
clinical endpoint together with the total analgesic consump-
tion over the first 12, 24, or 48 h. Consumption should be
expressed in micrograms or milligrams per kilogram per hour
(or per 24 h) so as to enable comparison. Ideally, these
endpoints should be combined with scores obtained from
validated pain assessment instruments.
Safety/adverse effects
Documentation of drug safety is highly important, espe-
cially in pediatric drug trials. There is some debate on
Eur J Clin Pharmacol (2011) 67 (Suppl 1):S61–S66 S63whether it is better to have a pre-defined list of possible
adverse events to be taken into account or to resort to an
unstructured approach in which researchers, parents, and/or
other individuals report any suspected adverse event [22].
This latter approach may carry the risk of underreporting of
adverse events.
Safe and effective pain treatment in neonates and young
infants requires a thorough understanding of various
developmental aspects of drug disposition and metabolism.
In general, the phenotypic variation in drug disposition and
metabolism is based on constitutional, genetic and environ-
mental factors. The clearance rate of most drugs is lower
in neonates than in adults and older children as neonates
still show immature renal function, i.e., decreased
glomerular filtration rate and less effective tubular
reabsorption and/or excretion. Moreover, they have a
lower capacity of drug metabolizing enzymes [39–44].
Furthermore, as reviewed by both Weinshillboum [45]a n d
Evans and McLeod [46], the disposition and action of many
drugs are polygenetic determined events, with polymor-
phisms in drug-metabolizing enzymes, transporters, and
receptors determining to a large extent the spectrum of drug
response (i.e., ranging from no effect to drug toxicity).
Long-term effects of analgesic treatment
The short- and long-term consequences of prolonged opioid
use in newborns and infants are largely unknown. Studies
in animals suggest potential adverse long-term effects of
morphine. Morphine administration to neonatal rats has been
found to produce long-term changes in behavior and brain
function[63] and to impair cognitive functioning in the adult
rat in general [64] and spatial recognition memory in
particular [65]. Basic science has shown that the opioid
system modulates neural proliferation in vivo [66]. Thus, it
may well be that morphine treatment harms the neurogenesis
of newborn babies. At the mechanistic level, morphine
induces the apoptosis of human microglial cells [67]a n d
stimulates red neuron degeneration in the rat brain, which
may lead to cerebral dysfunction [68]. Boasen et al. recently
showed in rodents that separate neonatal stress and morphine
treatments could independently of each other produce long-
lasting behavioral effects to a degree sufficient to alter
learning, while the combination of neonatal stress and
morphine did not [69].
Endpoints in human studies should therefore include
cognition, neuropsychological tests, a chronic pain
questionnaire, and pain and detection thresholds. The
latter thresholds may be assessed with quantitative
sensory testing (QST), for which normal values are
available [70].
Finally, we should realize that behavioral assessment
instruments reveal other aspects of the phenomenon pain
than do neurophysiological evaluation or the use of
biomarkers. Moreover, no single parameter covers the
whole spectrum from a nociceptive stimulus to behavior.
It therefore appears to be essential to also evaluate the fate
of drugs in the body (pharmacokinetics) as well as the
response of the body (pharmacodynamics).
Pharmacokinetics of the parent drug and (active)
metabolites in relation to pharmacodynamics
It has become easier to measure plasma levels of drugs in
children. Sophisticated analytical methods (e.g., liquid
chromatography/tandem mass spectrometry) and statistical
analyses (e.g., population pharmacokinetics/pharmacody-
namics, such as NONMEM) require smaller and fewer
samples [71]. A possible relationship between therapeutic
plasma ranges and pharmacodynamic parameters has not
yet been found. Mutation analysis can provide answers to
individual aberrant responses, although the tailoring of
analgesic dosing has still a long way to go [72].
Efforts to improve pain therapy, for example by means
of RCTs, should be developed within the context of
regulatory initiatives. American legislation (‘Food and
Drug Administration Modernization Act’ in 1997, ‘Best
Pharmaceuticals for Children Act’ in 2002, and ‘Pediatric
Research Equity Act’ in 2003) has come into force to
promote drug development and the authorization of
medicines for use in pediatric patients. Similar legislation
was introduced in the European Union in January 2007
(‘The Pediatric Regulation’) (full text on www.fda.gov and
www.emea.europe.eu). These legislations and clinical trial
registers (http://clinicaltrials.gov) provide essential infor-
mation on ongoing studies in other centers and prevent the
duplication of studies in this vulnerable age group.
Summary
Tools to measure pain are currently being used as primary
endpoints in studies on the effects of analgesic drugs.
Nevertheless, further research is needed to develop
more objective pain measurements, to identify causes of
variation in pain intensity and responses to pain
treatment (both non-pharmacological and pharmacologi-
cal PK-PD), and to develop age- and disease-specific
pain treatment protocols.
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